EMA Authorised: Svariya (previously Rivaroxaban Koanaa) (rivaroxaban) — Koanaa Healthcare GmbH

View source ↗

Summary

EMA authorised Svariya (rivaroxaban) for prevention and treatment uses related to thromboembolic conditions; managed by Koanaa Healthcare GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Embolism
• Pulmonary Embolism
• Stroke
• Venous Thromboembolism
• Venous Thrombosis

Drugs mentioned

• Svariya (rivaroxaban)

Snippet

Status: Authorised. Therapeutic area: Venous Thromboembolism;Pulmonary Embolism;Venous Thrombosis;Stroke;Embolism. MAH: Koanaa Healthcare GmbH. Decision date: 29/07/2026